Navigation Links
Discovery could lead to anti-clotting drugs with less risk of bleeding
Date:10/28/2013

Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing. By blocking this switch in lab mice, the researchers prevented small clots from growing -- a process that can pose a danger in humans -- while preserving their ability to staunch bleeding. Their findings, published online in Nature, open up the possibility for developing potent anti-clotting drugs that don't raise the risk of bleeding.

"Existing anti-clotting drugs significantly reduce the body's ability to form blood clots, so people on these drugs are at risk of serious bleeding," says Xiaoping Du, professor of pharmacology in the UIC College of Medicine and lead author of the paper. "By exploiting this switch we found, we can develop very powerful drugs that prevent the big clots that cause heart attacks and strokes, while preserving the body's ability to form the smaller, primary clots you need to stop bleeding."

Anti-clotting drugs, also known as blood thinners, can help prevent strokes, heart attacks, and deep vein clots. They are also prescribed to reduce the risk of dangerous clots after surgery. But the drugs also increase the risk of bleeding, and must be used with great care.

Du and colleagues investigated a protein called integrin, found in the cell membrane of platelets, the specialized blood cells that form clots to stop bleeding. Signals given off by injured or torn blood vessels activate integrin, which directs the platelets to bind to the injured blood vessel and to other platelets through a linking-protein called fibrinogen. This cross-linking results in a primary clot, good enough to stop the bleeding in most minor cuts.

The UIC researchers discovered that once fibrinogen gets involved, another molecule called G-alpha-13 latches on to integrin and causes the clot to grow much bigger -- to ensure the bleeding is stopped. Normally, the enlarged clot will shrink back. But in people prone to developing dangerous clots, or in those with narrowed arteries, the enlarged clots can lead to a heart attack or stroke.

Having found that G-alpha-13 is responsible for ramping up the clotting process, the researchers were able to develop a molecule that blocks G-alpha-13 from binding to integrin. Mice given the blocker-drug can form primary clots that stop bleeding but never enter the growth phase.

"This is exciting, because new drugs based on blocking G-alpha-13 can preserve the ability to form primary clots, which are necessary to heal wounds, but will prevent the clots from growing too large and clogging blood vessels," Du said.


'/>"/>

Contact: Sharon Parmet
sparmet@uic.edu
312-413-2695
University of Illinois at Chicago
Source:Eurekalert

Related medicine news :

1. Scientist awarded $1 million grant to develop tools for hepatitis C treatment discovery
2. Washingtons Life Sciences Discovery Fund awards commercialization grants
3. Discovery could help to develop drugs for organ transplant and cancer patients
4. Feelings of immaturity accompany alcohol misuse into adulthood; discovery could improve treatments
5. H1N1 discovery paves way for universal flu vaccine: UBC research
6. Scientists make breakthrough in bile duct cancer with discovery of new gene mutations
7. Researchers make promising discovery in pursuit of effective lymphoma treatments
8. Discovery suggests new combination therapy strategy for basal-like breast cancers
9. Discovery of Gene May Lead to New Male Contraceptive
10. 5 more pharmaceutical companies join NIH initiative to speed therapeutic discovery
11. Illnesses in Colorado childrens hospital prompts discovery of contaminated alcohol pads
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... , ... Comfort Keepers® of San Diego, CA is excited to announce they ... to drive cancer patients to and from their cancer treatments. Comfort Keepers provides ... life and ongoing independence. Getting to and from medical treatments is one of ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... , June 23, 2016 ... Oticon , industry leaders in advanced ... launch of Oticon Opn ™, the world,s first ... of possibilities for IoT devices.      (Photo: ... Oticon introduces a number of ,world firsts,: ...
Breaking Medicine Technology: